Crizotinib-induced fatal fulminant liver failure. (March 2016)

• Record Type: Journal Article
• Authors: van Geel, Robin M.J.M.; Hendrikx, Jeroen J.M.A.; Vahl, Jelmer E.; van Leerdam, Monique E.; van den Broek, Daan; Huitema, Alwin D.R.; Beijnen, Jos H.; Schellens, Jan H.M.; Burgers, Sjaak A.
• Is Part Of: Lung cancer. Volume 93(2016)
• Page Start: 17
• Page End: 19
• Publication Date: 2016-03
• Subjects: Crizotinib -- Hepatotoxicity -- Fulminant liver failure -- Non-small cell lung cancer; Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2015.12.010
• Languages: English
• ISSNs: 0169-5002

Abstract

Highlights: Report about a case of crizotinib-induced fulminant liver failure. Bilirubin levels kept increasing after crizotinib discontinuation. Symptoms of encephalopathy and hepatorenal syndrome emerged. Patient died due to acute liver failure with massive liver cell necrosis. Abstract: Herein we describe a case of a 62-year-old female in good clinical condition with non-small-cell lung cancer who was treated with crizotinib. After 24 days of crizotinib therapy she presented with acute liver failure. Serum aspartate aminotransferase and alanine aminotransferase levels had increased from normal prior to crizotinib start to 2053 IU/L and 6194 IU/L, respectively. Total bilirubin and prothrombin time (PT-INR) increased up to 443 IU/L and 5.33, respectively, and symptoms of hepatic encephalopathy and hepatorenal syndrome emerged. Despite crizotinib discontinuation and intensive supportive therapy, the patient died 40 days after treatment with crizotinib was initiated due to acute liver failure with massive liver cell necrosis.